FIELD: chemistry.
SUBSTANCE: invention relates to novel pyrazolopyridin-4-amines, pyrazoloquinoline-4-amines, pyrazolonaphthyridine-4-amines and 6,7,8,9-tetrahidropyrazoloquinoline-4-amines, pharmaceutical compositions based on said compounds, which can be used as immunomodulators for inducing or suppressing biosynthesis of cytokines in aminals and when treating viral and malignant diseases.
EFFECT: obtaining novel biologically active compounds.
24 cl, 197 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2011 |
|
RU2661410C2 |
| USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | 2010 |
|
RU2600869C2 |
| SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | 2005 |
|
RU2385867C2 |
| TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2013 |
|
RU2665134C2 |
| BICYCLIC COMPOUNDS AS PD1/PD-L1 INTERACTION/ACTIVATION INHIBITORS | 2019 |
|
RU2777980C2 |
| ANALOGUES OF BENZOQUINONE-CONTAINING ANSAMYCINS (VERSIONS), METHOD FOR PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION (VERSIONS) AND CANCER TREATMENT METHOD (VERSIONS) | 2004 |
|
RU2484086C9 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
| COMBINATED INHIBITORS OF FBP-ASE AND ANTIDIABETIC AGENTS FOR DIABETES TREATMENT | 2001 |
|
RU2328308C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| IMMUNOMODULATOR-CONTAINING PHARMACEUTICAL FORMULATIONS | 2002 |
|
RU2327460C2 |
